Organon & Co. Selling, General and Administrative Expense
Organon & Co. (OGN) reported Selling, General and Administrative Expense of $434.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-07-31
- Organon & Co. selling, general and administrative expense for the quarter ending 2026-06-30 was $434.00M, a 4.19% decline year-over-year.
- Organon & Co. selling, general and administrative expense for the quarter ending 2026-03-31 was $424.00M, a 0.95% increase year-over-year.
- Organon & Co. selling, general and administrative expense for the quarter ending 2025-12-31 was $433.00M, a 7.87% decline year-over-year.
- Organon & Co. selling, general and administrative expense for the quarter ending 2025-09-30 was $415.00M, a 1.66% decline year-over-year.
- Organon & Co. selling, general and administrative expense for fiscal 2025 was $1.72B, a 2.22% decline from fiscal 2024.
- Organon & Co. selling, general and administrative expense for fiscal 2024 was $1.76B, a 7.03% decline from fiscal 2023.
- Organon & Co. selling, general and administrative expense for fiscal 2023 was $1.89B, a 11.09% increase from fiscal 2022.
- Organon & Co. selling, general and administrative expense for fiscal 2022 was $1.70B, a 2.16% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $434.00M 10-Q · filed 2026-07-31 | $858.00M 10-Q · filed 2026-07-31 | $1.29B derived: sum of 3 quarters · filed 2026-07-31 | $1.71B derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $424.00M 10-Q · filed 2026-05-04 | $857.00M derived: sum of 2 quarters · filed 2026-05-04 | $1.27B derived: sum of 3 quarters · filed 2026-05-04 | $1.73B derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $433.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $848.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.30B derived: sum of 3 quarters · filed 2026-07-31 | $1.72B 10-K · filed 2026-02-24 |
| 2025-09-30 | $415.00M 10-Q · filed 2025-11-10 | $868.00M derived: sum of 2 quarters · filed 2026-07-31 | $1.29B 10-Q · filed 2025-11-10 | $1.76B derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $453.00M 10-Q · filed 2026-07-31 | $873.00M 10-Q · filed 2026-07-31 | $1.34B derived: sum of 3 quarters · filed 2026-07-31 | $1.76B derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $420.00M 10-Q · filed 2026-05-04 | $890.00M derived: sum of 2 quarters · filed 2026-05-04 | $1.31B derived: sum of 3 quarters · filed 2026-05-04 | $1.75B derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $470.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $892.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.33B derived: sum of 3 quarters · filed 2026-02-24 | $1.76B 10-K · filed 2026-02-24 |
| 2024-09-30 | $422.00M 10-Q · filed 2025-11-10 | $859.00M derived: sum of 2 quarters · filed 2025-11-10 | $1.29B 10-Q · filed 2025-11-10 | $1.76B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $437.00M 10-Q · filed 2025-08-06 | $868.00M 10-Q · filed 2025-08-06 | $1.34B derived: sum of 3 quarters · filed 2026-02-24 | $1.88B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $431.00M 10-Q · filed 2025-05-02 | $900.00M derived: sum of 2 quarters · filed 2026-02-24 | $1.44B derived: sum of 3 quarters · filed 2026-02-24 | $1.89B derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $469.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $1.01B derived: sum of 2 quarters · filed 2026-02-24 | $1.46B derived: sum of 3 quarters · filed 2026-02-24 | $1.89B 10-K · filed 2026-02-24 |
| 2023-09-30 | $538.00M 10-Q · filed 2024-11-01 | $989.00M derived: sum of 2 quarters · filed 2024-11-01 | $1.42B 10-Q · filed 2024-11-01 | $1.89B derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-06-30 | $451.00M 10-Q · filed 2024-08-07 | $886.00M 10-Q · filed 2024-08-07 | $1.36B derived: sum of 3 quarters · filed 2025-11-10 | $1.80B derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-03-31 | $435.00M 10-Q · filed 2024-05-03 | $905.00M derived: sum of 2 quarters · filed 2025-11-10 | $1.34B derived: sum of 3 quarters · filed 2025-11-10 | $1.77B derived: sum of 4 quarters · filed 2025-11-10 |
| 2022-12-31 | $470.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-10 | $910.00M derived: sum of 2 quarters · filed 2025-11-10 | $1.33B derived: sum of 3 quarters · filed 2025-11-10 | $1.70B 10-K/A · filed 2025-11-10 |
| 2022-09-30 | $440.00M 10-Q · filed 2023-11-03 | $863.00M derived: sum of 2 quarters · filed 2023-11-03 | $1.23B 10-Q · filed 2023-11-03 | $1.72B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $423.00M 10-Q · filed 2023-08-09 | $794.00M 10-Q · filed 2023-08-09 | $1.28B derived: sum of 3 quarters · filed 2024-02-26 | $1.66B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $371.00M 10-Q · filed 2023-05-05 | $853.00M derived: sum of 2 quarters · filed 2024-02-26 | $1.24B derived: sum of 3 quarters · filed 2024-02-26 | $1.66B derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $482.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $870.00M derived: sum of 2 quarters · filed 2024-02-26 | $1.29B derived: sum of 3 quarters · filed 2024-02-26 | $1.67B 10-K · filed 2024-02-26 |
| 2021-09-30 | $388.00M 10-Q · filed 2022-11-04 | $804.00M derived: sum of 2 quarters · filed 2022-11-04 | $1.19B 10-Q · filed 2022-11-04 | $1.62B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $416.00M 10-Q · filed 2022-08-05 | $798.00M 10-Q · filed 2022-08-05 | $1.23B derived: sum of 3 quarters · filed 2023-02-27 | $1.55B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $382.00M 10-Q · filed 2022-05-06 | $816.00M derived: sum of 2 quarters · filed 2023-02-27 | $1.14B derived: sum of 3 quarters · filed 2023-02-27 | $1.42B derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $434.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $755.00M derived: sum of 2 quarters · filed 2023-02-27 | $1.04B derived: sum of 3 quarters · filed 2023-02-27 | $1.36B 10-K · filed 2023-02-27 |
| 2020-09-30 | $321.00M 10-Q · filed 2021-11-12 | $605.00M derived: sum of 2 quarters · filed 2021-11-12 | $922.00M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $284.00M 10-Q · filed 2021-08-16 | $601.00M 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $317.00M 10-Q · filed 2021-06-21 | |||
| 2019-12-31 | $1.44B 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |